Table 5.
Odds ratio of having MetS in normal-weight versus overweight subjects with or without hepatic steatosis.
| Model 1* | Model 2** | Model 3*** | Model 4$ | |
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Normal weight and CAP < 238 dB/m | 1 | 1 | 1 | 1 |
| Normal weight and CAP ≥ 238 dB/m | 3.88 (2.02, 7.47) | 2.18 (1.08, 4.42) | 1.01 (0.27, 3.75) | 1.01 (0.27, 3.77) |
| Overweight and CAP < 238 dB/m | 4.75 (2.26, 9.97) | 1.21 (0.51, 2.90) | 0.42 (0.06, 2.72) | 0.56 (0.09, 3.70) |
| Overweight and CAP ≥ 238 dB/m | 16.40 (9.24, 29.09) | 3.86 (1.93, 7.74) | 4.80 (1.57, 14.67) | 3.24 (1.03, 10.2) |
| p for trend | 0.000 | 0.000 | 0.000 | 0.018 |
MetS, metabolic syndrome; CAP, controlled attenuation parameter; BMI, body mass index; UA, uric acid; TyG, the product of fasting triglycerides and glucose; LSM, liver stiffness measurement; ALT, alanine transaminase; AST, aspartate transaminase.
*Model 1 unadjusted.
**Model 2: adjusted for age, BMI, and waist.
***Model 3: adjusted for age, BMI, waist, adiponectin, UA, WBC, ALT, and TyG.
$Model 4: adjusted for gender, BMI, waist, waist-to-hip ratio, LSM, fasting insulin, creatinine, cholesterol, LDL-c, AST, fasting plasma glucose, and TyG.